Research map: Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal

Back to the article

Papers in this map

  1. Biochemistry and molecular cell biology of diabetic complications · Michael Brownlee · 2001 · 9147 citations · Cited by this paper
  2. Continuous glucose monitoring metrics based clustering in people living with type 1 diabetes identifies phenotypes associated with higher inflammation, metabolic dysfunction-associated steatotic liver disease risk, and lower insulin sensitivity · 2026 · Related
  3. Diabetic Neuropathy: A Position Statement by the American Diabetes Association · Rodica Pop‐Busui · 2016 · 2590 citations · Cited by this paper
  4. Relationship between hs-CRP-triglyceride glucose index and coronary plaque morphology: insights from optical coherence tomography · 2026 · Related
  5. Diabetic Cardiovascular Autonomic Neuropathy · Aaron I. Vinik · 2007 · 1259 citations · Cited by this paper
  6. Dietary index for gut microbiota and risk of metabolic syndrome: the mediating role of hepatic steatosis in a prospective cohort study · 2026 · Related
  7. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis · Ele Ferrannini · 2016 · 993 citations · Cited by this paper
  8. Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review · 2026 · Related
  9. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management · Vincenza Spallone · 2011 · 972 citations · Cited by this paper
  10. SGLT2 inhibitors: Do they have antiarrhythmic properties? · 2026 · Related
  11. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy · Hans‐Peter Hammes · 2003 · 788 citations · Cited by this paper
  12. GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies · 2025 · Related
  13. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function · Volker Vallon · 2020 · 514 citations · Cited by this paper
  14. SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort study · 2025 · Related
  15. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss · Mohit Sodhi · 2023 · 455 citations · Cited by this paper
  16. National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss · 2026 · Related
  17. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice · Bo-Wen Lin · 2014 · 430 citations · Cited by this paper
  18. Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method · 2026 · Related
  19. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis · Henning Bliddal · 2024 · 407 citations · Cited by this paper
  20. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach · 2025 · Related
  21. Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy · Dan Ziegler · 2011 · 398 citations · Cited by this paper
  22. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications · Saleh Hadi Alharbi · 2024 · 339 citations · Cited by this paper
  23. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer · Julien Bezin · 2022 · 313 citations · Cited by this paper
  24. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality – A systematic review and dose–response meta-analysis of prospective studies · Dagfinn Aune · 2017 · 288 citations · Cited by this paper
  25. SGLT2 Inhibitor–Induced Sympathoinhibition · Lakshini Yasaswi Herat · 2020 · 237 citations · Cited by this paper
  26. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial · Wataru Shimizu · 2020 · 237 citations · Cited by this paper
  27. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy · Rodica Pop‐Busui · 2022 · 229 citations · Cited by this paper
  28. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2 · Vance Bruce Matthews · 2017 · 226 citations · Cited by this paper
  29. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial · Solomon Hailemariam Tesfaye · 2022 · 209 citations · Cited by this paper
  30. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes · Duy Do · 2024 · 206 citations · Cited by this paper
  31. The Effects of SGLT2 Inhibitors on Lipid Metabolism · Zsolt János Szekeres · 2021 · 202 citations · Cited by this paper
  32. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations · Dan Ziegler · 2021 · 199 citations · Cited by this paper
  33. Efficacy of α-lipoic acid in diabetic neuropathy · Νικόλαος Παπάνας · 2014 · 194 citations · Cited by this paper
  34. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction · Nannan Zhang · 2019 · 176 citations · Cited by this paper
  35. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? · Jennifer Linge · 2024 · 169 citations · Cited by this paper
  36. Metabolic syndrome and peripheral neuropathy · Mohamed Kazamel · 2020 · 165 citations · Cited by this paper
  37. Weight regain after cessation of medication for weight management: systematic review and meta-analysis · Sam West · 2026 · 150 citations · Cited by this paper
  38. Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement · Kariem El‐Boghdadly · 2025 · 135 citations · Cited by this paper
  39. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults · Francesca L. Celletti · 2025 · 135 citations · Cited by this paper

Source: OpenAlex (CC0)